Fundraising Fox

Synthego

Redwood City, US · Founded 2012 · Delaware corporation · 176 employees on LinkedIn · 21 known investors

Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

Synthego was founded in 2012 by Paul John Dabrowski and Michael Jakub Dabrowski.

PJPaul John Dabrowski
Paul John DabrowskiCo-founder
MJ
Michael Jakub DabrowskiCo-founder

Board

DODrew Oetting
Drew Oettingin𝕏Board directorFounding partner of 8VC
SNScott Nolan
Scott Nolanin𝕏Board directorPartner at Founders Fund

Investors · 21

AAF Management Ltd.Washington
AME Cloud VenturesPalo Alto · $1M – $10M
Declaration PartnersNew York
Founders FundSan Francisco · $500K – $5Mvia Scott Nolan · board
Khosla VenturesMenlo Park · $5K – $50M
Menlo VenturesSan Francisco · $1M – $20M
Open Field CapitalNew York
Perot JainDallas · $500K
SoftBank Vision FundLondon
8VCreported · 2 sourcesAustin · $100K – $50M
GigafundreportedAustin · $1M – $5M
Intel CapitalreportedSanta Clara · $1M – $20M
OS Fundreported · 2 sourcesPark Ridge · $1M – $2M
RA Capitalreported · 2 sourcesBoston
Wellington ManagementreportedBoston · $5M – $50M

Also in the syndicate · 6

Chimera Abu DhabiLaurion Capital ManagementLogos CapitalMoore Strategic VenturesPerceptive AdvisorsleadSoftBank Vision Fund 2

Funding

SEC filings, press & company announcements

$147M disclosed across 2 of 4 rounds · 2016–2025

▶$106.3MraisedOct 2018 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Drew OettingDirector
  • Scott NolanDirector
  • Michael Jakub DabrowskiExecutive Officer, Director
  • Forrest Baringer-JonesExecutive Officer
  • Paul John DabrowskiExecutive Officer, Director
Offering amount
$116.3M
Amount sold
$106.3M
First sale
Oct 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40.7MraisedJan 2017 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul John DabrowskiExecutive Officer, Director
  • Michael Jakub DabrowskiExecutive Officer, Director
  • Drew OettingDirector
  • Scott NolanDirector
Offering amount
$40.7M
Amount sold
$40.7M
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

5 people who came through Synthego went on to found or lead other companies.

Drew OettingDirectorFounded 8Vc +1Scott NolanDirectorFounded General MatterHumberto EvansSoftware EngineerFounded CircuitLabFabian GerlinghausChief Innovation OfficerFounded CellaresOmar KurdiVP OperationsFounded Cellares

Competitors · 2

by search overlap
CRISPR878 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.
Read on Scientific American755 shared keywordsScientific American is a media organization that publishes research and ideas across science, health, technology and society through multiple formats including print, web, video, and podcasts. Founded in 1845, it reaches over 20 million people monthly and maintains editorial independence while providing trustworthy science communication and commentary.

Companies competing with Synthego for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Synthego: Perceptive Takes CRISPR Assets in $85M Credit Bidelevenflo.com · Jan 2026Bay Area biotech company Synthego, raised $392M, forced into bankruptcysfgate.com · May 2025Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-Phase Research to the Clinicsynthego.com · Feb 2022Synthego raises $100 mn Series D funding led by Wellington Management, makes executive changes | hrnxt.comhrnxt.com · Aug 2020Synthego Raises $100 Million in Series D Financingsynthego.com · Aug 2020Synthego raises $100 million for AI-driven gene editing - Synthegosynthego.com · Aug 2020Synthego Raises $41 Million in Series B Financing Led by 8VC to Advance CRISPR Genome Engineeringfinance.yahoo.com · Jan 2017

Frequently asked questions

What does Synthego do?
Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
Who founded Synthego?
Synthego was founded by Paul John Dabrowski, Michael Jakub Dabrowski in 2012.
Who are Synthego's investors?
Synthego's investors include AAF Management Ltd., AME Cloud Ventures, Declaration Partners, Founders Fund, Khosla Ventures, Menlo Ventures, Open Field Capital, Perot Jain and 7 more.
How much funding has Synthego raised?
Synthego has disclosed $147M raised across 2 of its 4 known rounds.
Where is Synthego headquartered?
Synthego is headquartered in Redwood City, US.